Protocolo del manejo de la hipertensión arterial refractaria, mediante ablación renal con radiofrecuencia por cateterismo arterial vía femoral. Experiencia del Hospital Central Militar
Contenido principal del artículo
Resumen
La hipertensión arterial es un grave problema social y económico en nuestra sociedad y por el aumento considerable de la morbimortalidad cardiovascular que trae consigo, así como su elevada prevalencia. En nuestro país sólo 50% de 100% de los pacientes que padecen hipertensión están diagnosticados.
Detalles del artículo
Sección
Cómo citar
Referencias
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;
: 217-23.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, et al. Management of Arterial Hyper-tension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, , et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
Kaplan NM. Resistant hypertension. J Hypertens 2005; 23: 1441-4.
Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep 2006; 8: 403-8.
DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197.
Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953; 1: 403-8.
Allen TR. Current status of lumbar sympathectomy. Am Surg 1976; 42: 89-91.
Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25:
-82.
Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-7.
Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-9.
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
Schlaich MP, Sobotka PA, Krum H, Lambert EA, Esler MD. Renal sympathetic nerve ablation for the treatment of uncontrolled hypertension. N Engl J Med 2009; 361: 932-34.
Wilson RF, Christensen BV, Olivari MT, Simon A, White CW, Laxson DD. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation 1991; 83: 1210-20.
Chapleau M. Arterial Baroreflexes. Hypertension Primer: The Essentials of High Blood Pressure. 2nd. Ed. London: Lippincott Williams & Wilkins; 1999, p. 83.
Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004; 43: 306-11.
Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, Pertile T, Kieval R, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006; 44: 1213-18.
Schmidli J, Savolainen H, Eckstein F, Irwin E, Peters TK, Martin R, Kieval R, et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular 2007; 15: 63-9.
Rothstein M. Chronic treatment of resistant hypertension with an implantable device: interim two-year results of two studies of the Rheos hypertension system. Presented at ACC 2009, Orlando, FL, USA.
Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619-26.
Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, et al. Novek baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study. J Am Coll Cardiol 2010; 56: 1254-8.
http://clinicaltrials.gov/ct2/show/NCT00442286?term=rheos&rank=1Clinicaltrials. govIdentifierNCT00442286. (2 July 2010).
Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.